| Symbol | BNTX |
|---|---|
| Name | BIONTECH SE |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | AN DER GOLDGRUBE 12, MAINZ, D-55131, Germany |
| Telephone | +49 613190840 |
| Fax | — |
| — | |
| Website | https://www.biontech.de |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioNTech SE is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The companys oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product. Additional info from NASDAQ: |
2026-04-23 20:02
Poetting Sierk 🔴 sold 50.0K shares of BioNTech SE (BNTX) at $110.56 ($5.5M) Transaction Date: Apr 22, 2026 | Filing ID: 000002
Read more
2026-04-21 10:45
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
Read more
2026-04-21 10:45
BioNTech veröffentlicht am 5. Mai 2026 Ergebnisse für das erste Quartal 2026 und informiert über operativen Fortschritt
Read more
2026-04-13 17:02
New Form 3/A - BioNTech SE <b>Filed:</b> 2026-04-13 <b>AccNo:</b> 0002123975-26-000004 <b>Size:</b> 4 KB
Read more
2026-04-11 11:00
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
Read more
2026-04-11 11:00
BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs
Read more
2026-04-01 17:16
New Form 20-F/A - BioNTech SE <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001776985-26-000023 <b>Size:</b> 438 KB
Read more
2026-03-25 19:05
New Form 3 - BioNTech SE <b>Filed:</b> 2026-03-25 <b>AccNo:</b> 0002124143-26-000002 <b>Size:</b> 21 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone o… | Phase1 | Advanced Renal Cell Carcinoma (RCC) | Recruiting | 2026-04-30 | 2031-11-26 | ClinicalTrials.gov |
| NCT07455734 | Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in A… | Phase1 | Advanced Solid Tumor Cancer | Recruiting | 2026-03-30 | 2030-10-01 | ClinicalTrials.gov |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradia… | Phase3 | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-03-16 | 2033-12-31 | ClinicalTrials.gov |
| NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combin… | Phase1 | Hepatocellular Carcinoma (HCC) | Recruiting | 2026-03-16 | 2031-10-14 | ClinicalTrials.gov |
| NCT07221149 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Ch… | Phase2 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Recruiting | 2026-03-13 | 2032-09-11 | ClinicalTrials.gov |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participa… | Phase3 | Non-Small Cell Lung Cancer (NSCLC) | Recruiting | 2026-03-12 | 2031-10-14 | ClinicalTrials.gov |
| NCT07365995 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant… | Phase3 | Metastatic Castration-resistant Prostate Cancer | Not_Yet_Recruiting | 2026-03-01 | 2031-02-01 | ClinicalTrials.gov |
| NCT07379580 | A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immun… | Phase2 | Mpox (Monkeypox) | Recruiting | 2026-02-20 | 2027-06-01 | ClinicalTrials.gov |
| NCT07392372 | A Clinical Trial Investigating the Safety and Biological Activity of the Antibo… | Phase1 | HIV -1 Infection | Recruiting | 2026-02-09 | 2027-06-01 | ClinicalTrials.gov |
| NCT07297212 | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT3… | Phase2 | Recurrent Glioblastoma | Recruiting | 2026-01-15 | 2029-07-01 | ClinicalTrials.gov |
| NCT07221357 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Ch… | Phase2 | Untreated, Unresectable, or Metastatic Colorectal Cancer | Recruiting | 2025-12-31 | 2034-03-11 | ClinicalTrials.gov |
| NCT07300839 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years… | Phase3 | COVID-19 | Active_Not_Recruiting | 2025-12-10 | 2026-07-31 | ClinicalTrials.gov |
| NCT07255404 | A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How… | Phase2 | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | 2025-12-04 | 2028-08-01 | ClinicalTrials.gov |
| NCT07186842 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potenti… | Phase1 | Advanced Solid Cancers | Recruiting | 2025-11-18 | 2030-05-01 | ClinicalTrials.gov |
| NCT07222384 | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in … | Phase3 | COVID-19 | Active_Not_Recruiting | 2025-10-30 | 2026-07-31 | ClinicalTrials.gov |
| NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-… | Phase3 | Breast Neoplasms | Recruiting | 2025-10-30 | 2030-09-01 | ClinicalTrials.gov |
| NCT07111520 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 … | Phase1 | Non-small Cell Lung Cancer | Recruiting | 2025-09-22 | 2030-01-01 | ClinicalTrials.gov |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as … | Phase1 | Advanced Solid Tumor | Recruiting | 2025-08-27 | 2028-08-01 | ClinicalTrials.gov |
| NCT07070232 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe … | Phase1 | Advanced Solid Tumor | Recruiting | 2025-08-12 | 2029-10-01 | ClinicalTrials.gov |
| NCT07133750 | PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Co… | Phase2 | CRC (Colorectal Cancer) | Not_Yet_Recruiting | 2025-08-01 | 2029-08-01 | ClinicalTrials.gov |
| NCT06953089 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumo… | Phase2 | Solid Tumors | Recruiting | 2025-07-18 | 2030-06-30 | ClinicalTrials.gov |
| NCT07079631 | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Use… | Phase1 | Metastatic Colorectal Cancer | Recruiting | 2025-07-18 | 2031-05-01 | ClinicalTrials.gov |
| NCT07069309 | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) … | Phase3 | COVID-19 | Active_Not_Recruiting | 2025-07-08 | 2026-05-05 | ClinicalTrials.gov |
| NCT06940804 | A Clinical Study Investigating the Therapeutic Effects and Safety of an Investi… | Phase2 | Testicular Germ Cell Tumor | Withdrawn | 2025-07-01 | 2042-06-01 | ClinicalTrials.gov |
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Ch… | Phase3 | Endometrial Cancer | Recruiting | 2025-06-10 | 2029-11-01 | ClinicalTrials.gov |
| NCT06892548 | A Clinical Study to Investigate the Efficacy and Safety of an Investigational C… | Phase1 | Advanced Lung Cancer | Recruiting | 2025-05-02 | 2031-06-01 | ClinicalTrials.gov |
| NCT06827236 | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Calle… | Phase1 | Locally Advanced Breast Cancer | Recruiting | 2025-04-23 | 2029-05-01 | ClinicalTrials.gov |
| NCT06841055 | Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Thera… | Phase2 | Non-small Cell Lung Cancer | Recruiting | 2025-03-03 | 2028-10-01 | ClinicalTrials.gov |
| NCT06821061 | A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People | Phase1 | Influenza | Completed | 2025-02-10 | 2025-12-17 | ClinicalTrials.gov |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With C… | Phase3 | Extensive-stage Small-cell Lung Cancer | Recruiting | 2025-02-03 | 2029-03-01 | ClinicalTrials.gov |
| NCT06750185 | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for … | Phase1 | Advanced Solid Tumor | Recruiting | 2025-01-13 | 2028-06-01 | ClinicalTrials.gov |
| NCT06712316 | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemothera… | Phase2 | Non-small Cell Lung Cancer | Recruiting | 2025-01-07 | 2030-03-01 | ClinicalTrials.gov |
| NCT05630352 | A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy In… | Phase1 | COVID-19 | Withdrawn | 2025-01-06 | 2026-07-13 | ClinicalTrials.gov |
| NCT06534983 | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivoluma… | Phase2 | Muscle-invasive Urothelial Carcinoma | Recruiting | 2024-12-09 | 2034-01-06 | ClinicalTrials.gov |
| NCT06683352 | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People | Phase1 | Influenza,Human | Completed | 2024-11-11 | 2025-07-15 | ClinicalTrials.gov |
| NCT06449222 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for … | Phase2 | Locally Advanced Breast Cancer | Active_Not_Recruiting | 2024-08-26 | 2029-06-01 | ClinicalTrials.gov |
| NCT06449209 | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Pat… | Phase2 | Extensive-stage Small-cell Lung Cancer | Active_Not_Recruiting | 2024-08-05 | 2028-05-01 | ClinicalTrials.gov |
| NCT06469164 | A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses … | Phase1 | Bacterial Vaginosis | Completed | 2024-07-01 | 2025-07-31 | ClinicalTrials.gov |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Sol… | Phase1 | Malignant Solid Tumor | Terminated | 2024-05-14 | 2025-11-20 | ClinicalTrials.gov |
| NCT06069778 | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy … | Phase1 | Pancreatic Cancer | Terminated | 2024-03-27 | 2024-09-18 | ClinicalTrials.gov |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | Phase3 | HER2-positive Breast Cancer | Active_Not_Recruiting | 2024-01-29 | 2026-02-01 | ClinicalTrials.gov |
| NCT06018337 | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Ho… | Phase3 | Metastatic Breast Cancer | Active_Not_Recruiting | 2024-01-18 | 2028-07-01 | ClinicalTrials.gov |
| NCT06178991 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined … | Phase3 | Influenza | Completed | 2023-12-20 | 2024-11-26 | ClinicalTrials.gov |
| NCT06150183 | Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Sol… | Phase1 | Advanced Malignant Solid Tumor | Active_Not_Recruiting | 2023-11-30 | 2028-03-01 | ClinicalTrials.gov |
| NCT06057038 | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | Phase1 | Malignant Solid Tumor | Active_Not_Recruiting | 2023-11-24 | 2026-11-28 | ClinicalTrials.gov |
| NCT05968326 | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezoliz… | Phase2 | Adenocarcinoma, Pancreatic Ductal | Recruiting | 2023-10-18 | 2031-01-01 | ClinicalTrials.gov |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced End… | Phase2 | Advanced Endometrial Cancer | Withdrawn | 2023-10-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT05988203 | A Clinical Study Investigating the Safety and Immune Responses After Immunizati… | Phase1 | Monkeypox | Completed | 2023-09-21 | 2026-03-04 | ClinicalTrials.gov |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase1 | Advanced Solid Tumors | Recruiting | 2023-08-17 | 2028-05-01 | ClinicalTrials.gov |
| NCT05997290 | A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in H… | Phase2 | SARS-CoV-2 Infection | Completed | 2023-08-10 | 2025-03-13 | ClinicalTrials.gov |
| NCT05547464 | Safety and Immune Responses After Vaccination With Two Investigational RNA-base… | Phase1 | Tuberculosis | Active_Not_Recruiting | 2023-07-31 | 2027-01-01 | ClinicalTrials.gov |
| NCT05671510 | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhi… | Phase3 | Non Small Cell Lung Cancer | Recruiting | 2023-06-28 | 2028-08-31 | ClinicalTrials.gov |
| NCT05557591 | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab W… | Phase2 | Advanced Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2023-04-21 | 2028-05-16 | ClinicalTrials.gov |
| NCT05537038 | Safety and Immune Responses After Vaccination With Two Investigational RNA-base… | Phase1 | Tuberculosis | Completed | 2023-04-18 | 2025-12-08 | ClinicalTrials.gov |
| NCT05491317 | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a T… | Phase1 | Non-CNS Tumor | Terminated | 2023-03-08 | 2025-08-11 | ClinicalTrials.gov |
| NCT05703607 | A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults | Phase1 | Shingles | Terminated | 2023-01-25 | 2025-09-19 | ClinicalTrials.gov |
| NCT05653752 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell… | Phase1 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2022-12-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT05581641 | Safety and Immune Responses After Vaccination With an Investigational RNA-based… | Phase1 | Malaria | Completed | 2022-12-15 | 2024-09-06 | ClinicalTrials.gov |
| NCT05432583 | A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital He… | Phase1 | Genital Herpes Simplex Type 2 | Active_Not_Recruiting | 2022-12-08 | 2026-10-01 | ClinicalTrials.gov |
| NCT05541861 | Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy… | Phase1 | SARS-CoV-2 Infection | Completed | 2022-11-08 | 2024-11-22 | ClinicalTrials.gov |
| NCT05596734 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Mo… | Phase2 | Influenza, Human | Completed | 2022-10-28 | 2023-12-28 | ClinicalTrials.gov |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced… | Phase1 | Solid Tumor, Adult | Completed | 2022-10-24 | 2025-10-23 | ClinicalTrials.gov |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053… | Phase1 | Solid Tumor, Adult | Terminated | 2022-10-04 | 2024-05-24 | ClinicalTrials.gov |
| NCT05543616 | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Hea… | Phase3 | SARS-CoV-2 Virus | Active_Not_Recruiting | 2022-09-23 | 2026-07-23 | ClinicalTrials.gov |
| NCT05472038 | A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-… | Phase2 | SARS-CoV-2 Infection | Completed | 2022-07-26 | 2024-03-26 | ClinicalTrials.gov |
| NCT05438329 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Phase1 | Advanced Solid Tumor | Recruiting | 2022-07-19 | 2025-06-30 | ClinicalTrials.gov |
| NCT05142189 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of … | Phase1 | Non-Small Cell Lung Cancer | Recruiting | 2022-06-17 | 2031-11-01 | ClinicalTrials.gov |
| NCT05310084 | Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Thr… | Phase3 | SARS-CoV-2 Infection | Completed | 2022-04-20 | 2022-10-05 | ClinicalTrials.gov |
| NCT05262530 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive… | Phase1 | Solid Tumor | Terminated | 2022-03-22 | 2025-12-22 | ClinicalTrials.gov |
| NCT05150691 | A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase1 | HER2-positive Advanced Solid Tumor | Recruiting | 2022-01-31 | 2027-10-01 | ClinicalTrials.gov |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of B… | Phase1 | Solid Tumor | Terminated | 2022-01-18 | 2023-07-24 | ClinicalTrials.gov |
| NCT04895982 | Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunoco… | Phase2 | SARS-CoV-2 Infection, COVID19 | Completed | 2021-10-15 | 2023-07-23 | ClinicalTrials.gov |
| NCT05004181 | Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in … | Phase2 | SARS-CoV-2 Infection | Completed | 2021-08-25 | 2023-10-04 | ClinicalTrials.gov |
| NCT04949490 | A Trial Investigating the Safety and Effects of One or Two Additional Doses of … | Phase2 | COVID-19 | Completed | 2021-07-26 | 2022-09-16 | ClinicalTrials.gov |
| NCT04813627 | Epidemiological Study to Monitor Study Participants With Resected Stage II (Hig… | — | Colorectal Cancer Stage II | Active_Not_Recruiting | 2021-07-02 | 2026-04-01 | ClinicalTrials.gov |
| NCT04955626 | To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 B… | Phase3 | SARS-CoV-2 Infection | Completed | 2021-07-01 | 2023-05-25 | ClinicalTrials.gov |
| NCT04710043 | Dose Escalation Trial of BNT152+153 in Patients With Cancer | Phase1 | Solid Tumor | Completed | 2021-06-08 | 2025-09-10 | ClinicalTrials.gov |
| NCT04526899 | A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or … | Phase2 | Melanoma Stage III | Completed | 2021-05-19 | 2025-11-24 | ClinicalTrials.gov |
| NCT04883775 | Study of a New Technique for Imaging Pancreatic Cancer | Phase1 | Pancreatic Cancer | Completed | 2021-05-10 | 2025-01-27 | ClinicalTrials.gov |
| NCT04816669 | A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulat… | Phase3 | SARS-CoV-2 Infection | Completed | 2021-04-01 | 2021-12-02 | ClinicalTrials.gov |
| NCT04816643 | A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of… | Phase2 | SARS-CoV-2 Infection, COVID-19 | Completed | 2021-03-24 | 2023-12-08 | ClinicalTrials.gov |
| NCT04486378 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful W… | Phase2 | Colorectal Cancer Stage II | Recruiting | 2021-03-08 | 2030-08-01 | ClinicalTrials.gov |
| NCT04754594 | To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against CO… | Phase2 | SARS-CoV-2 Infection | Completed | 2021-02-16 | 2022-07-15 | ClinicalTrials.gov |
| NCT04713553 | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Mul… | Phase3 | SARS-CoV-2 Infection | Completed | 2021-02-15 | 2021-07-22 | ClinicalTrials.gov |
| NCT04455620 | BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Pat… | Phase1 | Solid Tumor | Terminated | 2021-01-26 | 2024-05-28 | ClinicalTrials.gov |
| NCT04534205 | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effect… | Phase2 | Unresectable Head and Neck Squamous Cell Carcinoma | Recruiting | 2021-01-07 | 2029-04-01 | ClinicalTrials.gov |
| NCT04649021 | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Heal… | Phase2 | SARS-CoV-2 | Completed | 2020-12-04 | 2022-01-09 | ClinicalTrials.gov |
| NCT04588480 | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccin… | Phase4 | SARS-CoV-2 Infection | Completed | 2020-10-21 | 2021-11-25 | ClinicalTrials.gov |
| NCT04537949 | A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVI… | Phase1 | Covid-19 | Completed | 2020-09-09 | 2022-02-07 | ClinicalTrials.gov |
| NCT04523571 | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Heal… | Phase1 | SARS-CoV-2 | Completed | 2020-07-28 | 2021-08-10 | ClinicalTrials.gov |
| NCT04368728 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA… | Phase2 | SARS-CoV-2 Infection | Completed | 2020-04-29 | 2023-02-10 | ClinicalTrials.gov |
| NCT04380701 | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against CO… | Phase1 | Infections, Respiratory | Completed | 2020-04-23 | 2022-04-13 | ClinicalTrials.gov |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) | Phase1 | Prostate Cancer | Terminated | 2019-12-19 | 2024-01-23 | ClinicalTrials.gov |
Total clinical trials: 93
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Temozolomide | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Bevacizumab | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Pumitamig | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| mFOLFIRINOX | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Nab-paclitaxel | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Pumitamig | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| Temozolomide | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Bevacizumab | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Pumitamig | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| mFOLFIRINOX | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Nab-paclitaxel | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Pumitamig | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| Temozolomide | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Bevacizumab | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Pumitamig | Other | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| mFOLFIRINOX | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Nab-paclitaxel | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Pumitamig | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi KP.2) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | Other | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Docetaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| Docetaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Gotistobart | Other | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| Docetaxel | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Pumitamig | Other | Phase PHASE2 | Non-small Cell Lung Cancer | RECRUITING | NCT06841055 |
| Matching placebo | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Eribulin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Carboplatin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Gemcitabine | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Pumitamig | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Matching placebo | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Eribulin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Carboplatin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Gemcitabine | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Pumitamig | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Matching placebo | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Eribulin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Carboplatin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Gemcitabine | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Pumitamig | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Matching placebo | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Eribulin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Carboplatin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Gemcitabine | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Pumitamig | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Matching placebo | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Eribulin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Carboplatin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Gemcitabine | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Pumitamig | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Matching placebo | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Eribulin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Carboplatin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Gemcitabine | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Pumitamig | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Matching placebo | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Eribulin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Carboplatin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Gemcitabine | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Pumitamig | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Matching placebo | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Eribulin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Carboplatin | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Gemcitabine | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Pumitamig | Other | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | RECRUITING | NCT07079631 |
| SoC chemotherapy treatment 2 | Drug | Phase PHASE1 | Metastatic Colorectal Cancer | RECRUITING | NCT07079631 |
| SoC chemotherapy treatment 1 | Drug | Phase PHASE1 | Metastatic Colorectal Cancer | RECRUITING | NCT07079631 |
| BNT327 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | RECRUITING | NCT07079631 |
| BNT314 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | RECRUITING | NCT07079631 |
| BNT327 | Other | Phase PHASE1 | Locally Advanced Breast Cancer | RECRUITING | NCT06827236 |
| BNT323 | Other | Phase PHASE1 | Locally Advanced Breast Cancer | RECRUITING | NCT06827236 |
| CA19-9-targeting monoclonal antibody | Other | Phase PHASE1 | Advanced Solid Cancers | RECRUITING | NCT07186842 |
| BNT329 | Other | Phase PHASE1 | Advanced Solid Cancers | RECRUITING | NCT07186842 |
| Topotecan | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06449209 |
| Paclitaxel | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06449209 |
| Carboplatin | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06449209 |
| Etoposide | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06449209 |
| BNT327 Dose Level 2 (DL2) | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06449209 |
| BNT327 Dose Level 1 (DL1) | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06449209 |
| BNT3214 | DRUG | Phase PHASE1 | Advanced Solid Tumor Cancer | RECRUITING | NCT07455734 |
| BNT351 | DRUG | Phase PHASE1 | HIV -1 Infection | RECRUITING | NCT07392372 |
| Prednisone/prednisolone | DRUG | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | NOT_YET_RECRUITING | NCT07365995 |
| Durvalumab | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07361497 |
| BNT162b2 Vaccine | BIOLOGICAL | Phase PHASE3 | COVID-19 | RECRUITING | NCT07300839 |
| Temozolomide | DRUG | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| Cabozantinib | DRUG | Phase PHASE1 | Advanced Renal Cell Carcinoma (RCC) | RECRUITING | NCT07293351 |
| Ipilimumab | DRUG | Phase PHASE1 | Advanced Renal Cell Carcinoma (RCC) | RECRUITING | NCT07293351 |
| BNT162b2 (2025/2026 formulation) | BIOLOGICAL | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07222384 |
| CAPOX | DRUG | Phase PHASE2 | Untreated, Unresectable, or Metastatic Colorectal Cancer | RECRUITING | NCT07221357 |
| FOLFIRI | DRUG | Phase PHASE2 | Untreated, Unresectable, or Metastatic Colorectal Cancer | RECRUITING | NCT07221357 |
| FOLFOX | DRUG | Phase PHASE2 | Untreated, Unresectable, or Metastatic Colorectal Cancer | RECRUITING | NCT07221357 |
| Capox | DRUG | Phase PHASE2 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | RECRUITING | NCT07221149 |
| Folfox | DRUG | Phase PHASE2 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | RECRUITING | NCT07221149 |
| CA19-9-targeting monoclonal antibody | DRUG | Phase PHASE1 | Advanced Solid Cancers | RECRUITING | NCT07186842 |
| BNT329 | DRUG | Phase PHASE1 | Advanced Solid Cancers | RECRUITING | NCT07186842 |
| Matching placebo | DRUG | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-paclitaxel/Paclitaxel | DRUG | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| BNT3212 | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07147348 |
| Chemotherapy Regimen 2 | DRUG | Phase PHASE2 | CRC (Colorectal Cancer) | NOT_YET_RECRUITING | NCT07133750 |
| Chemotherapy Regimen 1 | DRUG | Phase PHASE2 | CRC (Colorectal Cancer) | NOT_YET_RECRUITING | NCT07133750 |
| PM8002 | DRUG | Phase PHASE2 | CRC (Colorectal Cancer) | NOT_YET_RECRUITING | NCT07133750 |
| SoC | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT07111520 |
| Bevacizumab | DRUG | Phase PHASE2 | Recurrent Glioblastoma | RECRUITING | NCT07297212 |
| SoC chemotherapy treatment 2 | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | RECRUITING | NCT07079631 |
| SoC chemotherapy treatment 1 | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | RECRUITING | NCT07079631 |
| Paroxetine | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07070232 |
| BNT326 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT07111520 |
| BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) | BIOLOGICAL | Phase PHASE3 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07069309 |
| DB-1311/BNT324 | DRUG | Phase PHASE2 | Solid Tumors | RECRUITING | NCT06953089 |
| CLDN6 RNA-LPX | BIOLOGICAL | Phase PHASE2 | Testicular Germ Cell Tumor | WITHDRAWN | NCT06940804 |
| CLDN6 CAR-T | BIOLOGICAL | Phase PHASE2 | Testicular Germ Cell Tumor | WITHDRAWN | NCT06940804 |
| BNT324 | DRUG | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | NOT_YET_RECRUITING | NCT07365995 |
| BNT323 | DRUG | Phase PHASE1 | Locally Advanced Breast Cancer | RECRUITING | NCT06827236 |
| Licensed COVID-19 Vaccine | BIOLOGICAL | Phase PHASE1 | Influenza | COMPLETED | NCT06821061 |
| Licensed Influenza Vaccine 3 | BIOLOGICAL | Phase PHASE1 | Influenza | COMPLETED | NCT06821061 |
| Investigational COVID-19 Vaccine | BIOLOGICAL | Phase PHASE1 | Influenza | COMPLETED | NCT06821061 |
| BNT317 DL7 (additional) | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06750185 |
| BNT317 DL6 (intermediate) | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06750185 |
| BNT317 DL5 (intermediate) | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06750185 |
| BNT317 DL4 | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06750185 |
| BNT317 DL3 | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06750185 |
| BNT317 DL2 | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06750185 |
| BNT317 DL1 | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06750185 |
| Carboplatin (or cisplatin if carboplatin is not tolerated) | DRUG | Phase PHASE3 | Extensive-stage Small-cell Lung Cancer | RECRUITING | NCT06712355 |
| Pumitamig | DRUG | Phase PHASE3 | Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07361510 |
| Licensed Influenza Vaccine 2 | BIOLOGICAL | Phase PHASE1 | Influenza | COMPLETED | NCT06821061 |
| Licensed Influenza Vaccine 1 | BIOLOGICAL | Phase PHASE1 | Influenza | COMPLETED | NCT06821061 |
| Investigational Influenza Vaccine | BIOLOGICAL | Phase PHASE1 | Influenza | COMPLETED | NCT06821061 |
| Saline | DRUG | Phase PHASE2 | Muscle-invasive Urothelial Carcinoma | RECRUITING | NCT06534983 |
| Nivolumab | DRUG | Phase PHASE1 | Advanced Renal Cell Carcinoma (RCC) | RECRUITING | NCT07293351 |
| Autogene Cevumeran | DRUG | Phase PHASE2 | Muscle-invasive Urothelial Carcinoma | RECRUITING | NCT06534983 |
| BNT331 | DRUG | Phase PHASE1 | Bacterial Vaginosis | COMPLETED | NCT06469164 |
| BNT327 Equivalent Q3W Dose | DRUG | Phase PHASE2 | Locally Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06449222 |
| BNT327 Optimized Dose | DRUG | Phase PHASE2 | Locally Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06449222 |
| Eribulin | DRUG | Phase PHASE3 | Breast Neoplasms | RECRUITING | NCT07173751 |
| Nab-placlitaxel | DRUG | Phase PHASE2 | Locally Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06449222 |
| BNT327 Dose Level 1 (DL2) | DRUG | Phase PHASE2 | Locally Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06449222 |
| Topotecan | DRUG | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06449209 |
| BNT327 Dose Level 2 (DL2) | DRUG | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06449209 |
| BNT327 Dose Level 1 (DL1) | DRUG | Phase PHASE2 | Locally Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06449222 |
| Standard Chemotherapy | DRUG | Phase PHASE1 | Malignant Solid Tumor | TERMINATED | NCT06391775 |
| GEN1055 | BIOLOGICAL | Phase PHASE1 | Malignant Solid Tumor | TERMINATED | NCT06391775 |
| Doxorubicin | DRUG | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| BNT323/DB-1303 | DRUG | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT06340568 |
| T-DM1 | DRUG | Phase PHASE3 | HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06265428 |
| Investigational influenza vaccine | BIOLOGICAL | Phase PHASE3 | Influenza | COMPLETED | NCT06178991 |
| Influenza and COVID-19 Combination B | BIOLOGICAL | Phase PHASE3 | Influenza | COMPLETED | NCT06178991 |
| COVID-19 Vaccine | BIOLOGICAL | Phase PHASE1 | Influenza,Human | COMPLETED | NCT06683352 |
| Licensed influenza vaccine | BIOLOGICAL | Phase PHASE3 | Influenza | COMPLETED | NCT06178991 |
| Influenza and COVID-19 Combination A | BIOLOGICAL | Phase PHASE3 | Influenza | COMPLETED | NCT06178991 |
| BNT314 | BIOLOGICAL | Phase PHASE1 | Metastatic Colorectal Cancer | RECRUITING | NCT07079631 |
| BNT321 RP2D | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT06069778 |
| BNT321 DL 2 | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT06069778 |
| BNT321 0.5 mg/kg | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT06069778 |
| BNT165e | BIOLOGICAL | Phase PHASE1 | Malaria | ACTIVE_NOT_RECRUITING | NCT06069544 |
| 5-Fluorouracil | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Acasunlimab | BIOLOGICAL | Phase PHASE2 | Advanced Endometrial Cancer | WITHDRAWN | NCT06046274 |
| Capecitabine | DRUG | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06018337 |
| BNT162b2 (Omi KP.2) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi JN.1) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT162b2 (Omi XBB.1.5) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05997290 |
| BNT166a | BIOLOGICAL | Phase PHASE2 | Mpox (Monkeypox) | RECRUITING | NCT07379580 |
| mFOLFIRINOX | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| Abiraterone | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05914116 |
| Enzalutamide | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05914116 |
| itraconazole | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05914116 |
| Lopinavir and Ritonavir Tablets | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05914116 |
| DB-1311 | DRUG | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05914116 |
| Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection | BIOLOGICAL | Phase PHASE1 | Shingles | TERMINATED | NCT05703607 |
| Shingrix | BIOLOGICAL | Phase PHASE1 | Shingles | TERMINATED | NCT05703607 |
| Candidate 3: PF-07921186: VZV modRNA Suspension for Injection | BIOLOGICAL | Phase PHASE1 | Shingles | TERMINATED | NCT05703607 |
| Candidate 2: PF-07921188: VZV modRNA Suspension for Injection | BIOLOGICAL | Phase PHASE1 | Shingles | TERMINATED | NCT05703607 |
| Candidate 1: PF-07915234: VZV modRNA Suspension for Injection | BIOLOGICAL | Phase PHASE1 | Shingles | TERMINATED | NCT05703607 |
| Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection | BIOLOGICAL | Phase PHASE1 | Shingles | TERMINATED | NCT05703607 |
| Gotistobart | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT05671510 |
| YL202 | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05653752 |
| Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose | BIOLOGICAL | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT05630352 |
| tIRV | BIOLOGICAL | Phase PHASE2 | Influenza, Human | COMPLETED | NCT05596734 |
| bIRV | BIOLOGICAL | Phase PHASE2 | Influenza, Human | COMPLETED | NCT05596734 |
| QIV | BIOLOGICAL | Phase PHASE2 | Influenza, Human | COMPLETED | NCT05596734 |
| qIRV (22/23) | BIOLOGICAL | Phase PHASE2 | Influenza, Human | COMPLETED | NCT05596734 |
| bivalent BNT162b2 (original/Omi BA.4/BA.5) | BIOLOGICAL | Phase PHASE2 | Influenza, Human | COMPLETED | NCT05596734 |
| GEN1056 | BIOLOGICAL | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT05586321 |
| BNT165b1 | BIOLOGICAL | Phase PHASE1 | Malaria | COMPLETED | NCT05581641 |
| Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Virus | RECRUITING | NCT05543616 |
| Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Virus | RECRUITING | NCT05543616 |
| Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Virus | RECRUITING | NCT05543616 |
| Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Virus | RECRUITING | NCT05543616 |
| Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose | BIOLOGICAL | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT05630352 |
| Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose | BIOLOGICAL | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT05630352 |
| Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | BIOLOGICAL | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT05630352 |
| BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg | BIOLOGICAL | Phase PHASE1 | SARS-CoV-2 Infection | COMPLETED | NCT05541861 |
| BNT162b4 30 mcg | BIOLOGICAL | Phase PHASE1 | SARS-CoV-2 Infection | COMPLETED | NCT05541861 |
| BNT162b4 15 mcg | BIOLOGICAL | Phase PHASE1 | SARS-CoV-2 Infection | COMPLETED | NCT05541861 |
| BNT162b4 10 mcg | BIOLOGICAL | Phase PHASE1 | SARS-CoV-2 Infection | COMPLETED | NCT05541861 |
| BNT162b4 5 mcg | BIOLOGICAL | Phase PHASE1 | SARS-CoV-2 Infection | COMPLETED | NCT05541861 |
| BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg | BIOLOGICAL | Phase PHASE1 | SARS-CoV-2 Infection | COMPLETED | NCT05541861 |
| BNT164b1 | BIOLOGICAL | Phase PHASE1 | Tuberculosis | ACTIVE_NOT_RECRUITING | NCT05547464 |
| BNT164a1 | BIOLOGICAL | Phase PHASE1 | Tuberculosis | ACTIVE_NOT_RECRUITING | NCT05547464 |
| Radiotherapy | RADIATION | Phase PHASE1 | Non-CNS Tumor | TERMINATED | NCT05491317 |
| BNT162b7 Monovalent (OMI BA.4/BA.5) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05472038 |
| BNT162b7 Bivalent (Original/OMI BA.4/BA.5) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05472038 |
| BNT162b6 Bivalent (Original/OMI BA.4/BA.5) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05472038 |
| BNT162b5 Bivalent (Original/OMI BA.4/BA.5) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05472038 |
| BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05472038 |
| BNT162b2 Bivalent (WT/OMI BA.1) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05472038 |
| BNT162b5 Bivalent (WT/OMI BA.2) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05472038 |
| BNT327 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT07111520 |
| DB-1305/BNT325 | DRUG | Phase PHASE2 | Solid Tumors | RECRUITING | NCT06953089 |
| GEN1053 | BIOLOGICAL | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05435339 |
| BNT163 | BIOLOGICAL | Phase PHASE1 | Genital Herpes Simplex Type 2 | ACTIVE_NOT_RECRUITING | NCT05432583 |
| Seasonal Inactivated Influenza Vaccine | BIOLOGICAL | Phase PHASE3 | SARS-CoV-2 Infection | COMPLETED | NCT05310084 |
| BNT142 | BIOLOGICAL | Phase PHASE1 | Solid Tumor | TERMINATED | NCT05262530 |
| Itraconazole | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07070232 |
| Ritonavir | DRUG | Phase PHASE1 | HER2-positive Advanced Solid Tumor | RECRUITING | NCT05150691 |
| Pertuzumab Injection | DRUG | Phase PHASE1 | HER2-positive Advanced Solid Tumor | RECRUITING | NCT05150691 |
| DB-1303/BNT323 | DRUG | Phase PHASE3 | HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06265428 |
| Bispecific antibody for PD-L1 and VEGF-A | BIOLOGICAL | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT05142189 |
| anti-HER3 antibody conjugated to topoisomerase I inhibitor | BIOLOGICAL | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT05142189 |
| anti-B7-H3 antibody conjugated to topoisomerase I inhibitor | BIOLOGICAL | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT05142189 |
| BNT316 | BIOLOGICAL | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT05142189 |
| Docetaxel | DRUG | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | NOT_YET_RECRUITING | NCT07365995 |
| BNT116 | DRUG | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05557591 |
| Observational | OTHER | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05004181 |
| Monovalent BNT162b2 (B.1.1.529.1) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05004181 |
| Monovalent BNT162b2 (B.1.617.2) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05004181 |
| Monovalent BNT162b2 (B.1.1.7) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05004181 |
| Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT05004181 |
| Combination (Bivalent) BNT162b2 and BNT162b2 OMI | BIOLOGICAL | Phase PHASE3 | SARS-CoV-2 Infection | COMPLETED | NCT04955626 |
| Combination BNT162b2 and BNT162b2 OMI | BIOLOGICAL | Phase PHASE3 | SARS-CoV-2 Infection | COMPLETED | NCT04955626 |
| BNT162b2 OMI | BIOLOGICAL | Phase PHASE3 | SARS-CoV-2 Infection | COMPLETED | NCT04955626 |
| BNT162b2s01 | BIOLOGICAL | Phase PHASE2 | COVID-19 | COMPLETED | NCT04949490 |
| MVT-5873 | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT04883775 |
| MVT-2163 | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT04883775 |
| Biological/Vaccine: BNT162b2 3mcg | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection, COVID-19 | COMPLETED | NCT04816643 |
| BNT162b2 30mcg | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection, COVID-19 | COMPLETED | NCT04816643 |
| BNT162b2 20mcg | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection, COVID-19 | COMPLETED | NCT04816643 |
| Biological/Vaccine: BNT162b2 10mcg | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection, COVID-19 | COMPLETED | NCT04816643 |
| Regular blood sample collection for ctDNA assessment | PROCEDURE | Preclinical | Colorectal Cancer Stage II | ACTIVE_NOT_RECRUITING | NCT04813627 |
| BNT162b2.B.1.351 | BIOLOGICAL | Phase PHASE3 | SARS-CoV-2 Infection | COMPLETED | NCT04713553 |
| BNT153 | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04710043 |
| BNT152 | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04710043 |
| Nab-paclitaxel | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07255404 |
| BNT141 | DRUG | Phase PHASE1 | Solid Tumor | TERMINATED | NCT04683939 |
| BNT162b3 | BIOLOGICAL | Phase PHASE1 | Covid-19 | COMPLETED | NCT04537949 |
| BNT111 | BIOLOGICAL | Phase PHASE2 | Melanoma Stage III | COMPLETED | NCT04526899 |
| Observational group (no intervention) | OTHER | Phase PHASE2 | Colorectal Cancer Stage II | RECRUITING | NCT04486378 |
| RO7198457 intravenous (IV) | DRUG | Phase PHASE2 | Colorectal Cancer Stage II | RECRUITING | NCT04486378 |
| BNT151 | BIOLOGICAL | Phase PHASE1 | Solid Tumor | TERMINATED | NCT04455620 |
| Cemiplimab | DRUG | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05557591 |
| BNT112 | BIOLOGICAL | Phase PHASE1 | Prostate Cancer | TERMINATED | NCT04382898 |
| BNT162c2 | BIOLOGICAL | Phase PHASE1 | Infections, Respiratory | COMPLETED | NCT04380701 |
| BNT162a1 | BIOLOGICAL | Phase PHASE1 | Infections, Respiratory | COMPLETED | NCT04380701 |
| BNT162b2SA | BIOLOGICAL | Phase PHASE2 | SARS-CoV-2 Infection | COMPLETED | NCT04368728 |
| Placebo | DRUG | Phase PHASE1 | HIV -1 Infection | RECRUITING | NCT07392372 |
| BNT162b2 | BIOLOGICAL | Phase PHASE3 | SARS-CoV-2 Infection | COMPLETED | NCT05310084 |
| BNT162b1 | BIOLOGICAL | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04523571 |
| W_ova1 Vaccine | DRUG | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT04163094 |
| Etoposide | DRUG | Phase PHASE3 | Extensive-stage Small-cell Lung Cancer | RECRUITING | NCT06712355 |
| BNT411 | DRUG | Phase PHASE1 | Solid Tumor | TERMINATED | NCT04101357 |
| Paclitaxel | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Pemetrexed | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Nab paclitaxel | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Gemcitabine | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| 5-FU | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Carboplatin | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Cisplatin | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| GEN1042 | BIOLOGICAL | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| BNT113 | BIOLOGICAL | Phase PHASE2 | Unresectable Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT04534205 |
| Atezolizumab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma (HCC) | RECRUITING | NCT07291076 |
| Autogene cevumeran | DRUG | Phase PHASE2 | Adenocarcinoma, Pancreatic Ductal | RECRUITING | NCT05968326 |
| Pembrolizumab | DRUG | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Lymphocytic Leukemia | RECRUITING | NCT03219450 |
| NeoVax | DRUG | Phase PHASE1 | Lymphocytic Leukemia | RECRUITING | NCT03219450 |
| Lipo-MERIT | BIOLOGICAL | Phase PHASE1 | Melanoma | COMPLETED | NCT02410733 |
| IVAC_W_bre1_uID/IVAC_M_uID | BIOLOGICAL | Phase PHASE1 | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | COMPLETED | NCT02316457 |
| IVAC_W_bre1_uID | BIOLOGICAL | Phase PHASE1 | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | COMPLETED | NCT02316457 |
| APVAC2 vaccine plus Poly-ICLC and GM-CSF | DRUG | Phase PHASE1 | Glioblastoma | COMPLETED | NCT02149225 |
| APVAC1 vaccine plus Poly-ICLC and GM-CSF | DRUG | Phase PHASE1 | Glioblastoma | COMPLETED | NCT02149225 |
Total products: 413